cognitive cybersecurity intelligence

News and Analysis


Five NASH companies racing to get their treatments approved

NASH is a severe form of non-alcoholic fatty liver disease without any FDA-approved treatments. However, many companies are working towards an effective treatment, with several in late-stage trials. Five leading contenders are Galectin Therapeutics with its product belapectin; Galmed Pharmaceuticals with Aramchol; Inventiva Pharma with lanifibranor; Madrigal Pharmaceuticals with resmetirom; and 89bio with pegozafermin. The NASH treatment market is expected to reach $48.3 billion by 2035.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts